Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours if you need active treatment for cancer. These trials do not pay you for participation.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease Site Study Location
Disease Site: Bladder

ALLIANCE A031501   View on ClinicalTrials.gov
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION

OP Cancer Institute Research
864-241-6251
Disease Site: AML

Astellas 2215-CL-0201   View on ClinicalTrials.gov
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy.

OP Cancer Institute Research
864-241-6251
Disease Site: Lymphoma

CTSU EA4151   View on ClinicalTrials.gov
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

OP Cancer Institute Research
864-241-6251
Disease Site: Gastric/GE Junction

Arcus AB928CSP003   View on ClinicalTrials.gov
A phase I/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with gastrointestinal malignancies

ITOR
864-455-3600
Disease Site: Lymphoma

ALLIANCE A051301   View on ClinicalTrials.gov
A RANDOMIZED DOUBLE-BLIND PHASE III STUDY OF IBRUTINIB DURING AND FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS PLACEBO IN PATIENTSWITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAOF THE ACTIVATED B-CELL SUBTYPE

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

ALLIANCE A011502   View on ClinicalTrials.gov
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

OP Cancer Institute Research
864-241-6251
Disease Site: Colorectal

NRG GI004   View on ClinicalTrials.gov
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

OP Cancer Institute Research
864-241-6251
Disease Site: Supportive Care

SWOG S1501   View on ClinicalTrials.gov
PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III

OP Cancer Institute Research
864-241-6251
Disease Site: Pancreatic

CTSU EA2161   View on ClinicalTrials.gov
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) plan to open with CIRB when patient identified

OP Cancer Institute Research
864-241-6251
Disease Site: Supportive Care

WFU 97116   View on ClinicalTrials.gov
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

OP Cancer Institute Research
864-241-6251